Amicus Therapeutics (FOLD) Stock Surges Following Fabry Treatment Pill Results

NEW YORK (TheStreet) -- Shares of Amicus Therapeutics  (FOLD) surged 14.9% to $6.54 in morning trading Monday after the company announced positive results of its experimental pill migalastat in patients with Fabry disease.

Amicus said patients showed improvements in heart size and had fewer disease-related events in comparison to similar patients treated with currently improved injectable therapies. This data supports earlier results from a Phase III study the company announced in August.

Fabry is a rare genetic disease that causes fat to build up in the body and causes pain, loss of hearing and cloudy eyes. It eventually leads to kidney failure, stroke and death.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Amicus announced the new data at the American Society of Nephrology annual meeting on Saturday.

For more on this story, read TheStreet's Adam Feuerstein's in-depth coverage here.

FOLD Chart FOLD data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Wall Street Is Totally Forgetting Apple Will Be Giving Away Tons of Cash in 2018

Wall Street Is Totally Forgetting Apple Will Be Giving Away Tons of Cash in 2018

Tuesday's Premarket Movers: CAT, UTX, KO, MMM

Tuesday's Premarket Movers: CAT, UTX, KO, MMM

Vivendi Slides After Reports Vincent Bollore Questioned in Corruption Probe

Vivendi Slides After Reports Vincent Bollore Questioned in Corruption Probe

Alphabet, Caterpillar, Coca-Cola and Amazon - 5 Things You Must Know

Alphabet, Caterpillar, Coca-Cola and Amazon - 5 Things You Must Know

Alphabet's Earnings Beat and 4 Other Business Stories You Must Know Tuesday

Alphabet's Earnings Beat and 4 Other Business Stories You Must Know Tuesday